| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ANI Pharmaceuticals, Inc.$79.79
-0.27 (-0.34%)
D 33Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.70 B
EPS
4.09
P/E Ratio
18.94 $
Value Trade
19.33 M
SEC Financials
Q1 2026Dilution Risk
Revenue
237.46 M
R&D Expenses
10.60 M
Operating CF
58.38 M
Total Assets
1.42 B
Total Liabilities
859.67 M
Equity
562.30 M
4.34 %
Week
2.95 %
1 Month
6.21 %
3 Month
5.21 %
6 Month
134.93 %
5 Year
-72.32 %
All Time
Cash Data
Cash Position
311.18 M
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
139.06 K
52 Week Range
59.61 - 99.50
% held by Insiders
12.33 %
% held by Institutions
105.03 %
Enterprise Value
1.99 B
Total Shares
22.73 M
Short %
16.91 %
Float Shares
19.00 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ANI Pharmaceuticals, Inc.
517Total events
5Upcoming
149Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Oral Presentation
Subscribe to view catalyst details
Event history 2
TBD
▼IP Litigation RulingIP / Competition
Subscribe to view catalyst details
TBD
▲Primary Endpoint Metfluocinolone acetonideClinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-01-28 | Inzirqo (hydrochlorothiazide) | PDUFA Date | PDUFA | Approved | – | – | – |
2025-01-28 | Inzirqo (hydrochlorothiazide) | PDUFA Date | PDUFA | Approved | – | – | – |
2025-01-28 | Inzirqo (hydrochlorothiazide) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
D33
Pipeline Score $34M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 44%
Micro Cap (rank 518 of 923)
Percentile RankANI Pharmaceuticals, Inc. faces pipeline headwinds (33/100), with $85M risk-adjusted pipeline value, led by Fluocinolone Acetonide/Medidur in Age Related Macular Degeneration (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| fluocinolone acetonide Small molecule | Diabetic Macular Edema | Phase 3 | NCT00344968 | 49% | $85M | COMPLETED | 1,113 | - | - | Dec 1, 2010 | - | May 7, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Fluocinolone Acetonide Intravitreal Implant | chronic non-infectious uveitis | Phase 4 | 2026-07-13 | mean change BCVA: +3.6 letters gained (p= <0.0077); mean BCVA baseline: 62.5; mean BCVA month 6: 65.8; mean change CST: -157.5 microns (p= <.0001); mean CST baseline: 505.7 microns; mean CST month 6: 348.8 microns; treatment related AE percentage: 29% (n=31/108); ocular hypertension percentage: 6% (n=7); cataract percentage: 5% (n=5); IOP increase percentage: 18% (n=19/108); IOP lowering intervention percentage: 7% (n=8/108) Read More | ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis Read More | |
Fluocinolone Acetonide Intravitreal Implant | chronic non-infectious uveitis | Phase 4 | 2026-07-13 | mean change BCVA: +3.6 letters gained (p= <0.0077); mean BCVA baseline: 62.5; mean BCVA month 6: 65.8; mean change CST: -157.5 microns (p= <.0001); mean CST baseline: 505.7 microns; mean CST month 6: 348.8 microns; treatment related AE percentage: 29% (n=31/108); ocular hypertension percentage: 6% (n=7); cataract percentage: 5% (n=5); IOP increase percentage: 18% (n=19/108); IOP lowering intervention percentage: 7% (n=8/108) Read More | ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis Read More | |
Fluocinolone Acetonide Intravitreal Implant | chronic non-infectious uveitis | Phase 4 | 2026-07-13 | mean change BCVA: +3.6 letters gained (p= <0.0077); mean BCVA baseline: 62.5; mean BCVA month 6: 65.8; mean change CST: -157.5 microns (p= <.0001); mean CST baseline: 505.7 microns; mean CST month 6: 348.8 microns; treatment related AE percentage: 29% (n=31/108); ocular hypertension percentage: 6% (n=7); cataract percentage: 5% (n=5); IOP increase percentage: 18% (n=19/108); IOP lowering intervention percentage: 7% (n=8/108) Read More | ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANIP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANIP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANIPANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
ANI Pharmaceuticals will announce its second quarter 2026 financial results on August 7, 2026, at 8:00 a.m. ET. The announcement will be followed by a webcast and conference call hosted by key executives, including the CEO and CFO. The event will provide insights into the company's performance and future strategies.
Read more →ANIPANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
ANI Pharmaceuticals announced its intent to appeal a trial court's denial of its motion for a new trial regarding unjust enrichment claims against CG Oncology. The company seeks to recover the value of assets sold in 2010 and aims to secure a 5% royalty on future sales of a specific product. ANI's CEO expressed disagreement with the court's decision and commitment to pursue legal avenues.
Read more →ANIPANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
ANI Pharmaceuticals announced positive topline results from its Phase 4 SYNCHRONICITY trial, which evaluated the fluocinolone acetonide intravitreal implant in patients with chronic non-infectious uveitis. The trial met both co-primary endpoints, showing significant improvements in best corrected visual acuity and central subfield thickness at six months. Adverse events were consistent with prior studies, with a notable percentage of patients experiencing treatment-related issues.
Read more →ANIPANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
ANI Pharmaceuticals, Inc. announced that CEO Nikhil Lalwani will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The event will be accessible via a live and archived webcast on the company's website. ANI Pharmaceuticals focuses on developing and commercializing innovative therapeutics across various medical fields.
Read more →ANIPANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
ANI Pharmaceuticals reported strong financial results for Q1 2026, with net revenues of $237.5 million, a 20.5% increase from the previous year. The company raised its full-year guidance, expecting total revenues between $1.08 billion and $1.14 billion, driven largely by growth in its Rare Disease segment. Cortrophin Gel showed significant revenue growth, and the company is focused on expanding its market presence.
Read more →ANIPANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
ANI Pharmaceuticals will release its first quarter 2026 financial results on May 8, 2026. The announcement includes a conference call and webcast hosted by key executives to discuss the results. The company emphasizes its commitment to developing innovative therapeutics and sustainable growth in its Rare Disease business.
Read more →ANIPANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
ANI Pharmaceuticals has announced the FDA approval and launch of Pimozide Tablets, a generic version of Orap. The launch comes with 180-Day CGT exclusivity, allowing ANI to limit competition in the market. The annual sales for Pimozide Tablets are estimated at around $3.1 million, indicating a promising revenue opportunity for the company.
Read more →ANIPANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
ANI Pharmaceuticals has launched Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg dosages, marking a significant addition to its generics portfolio. This launch aims to enhance patient access to essential medications and is expected to tap into a market with annual sales of around $65 million. The company's commitment to quality and compliance remains a priority.
Read more →ANIPANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
ANI Pharmaceuticals has received FDA approval for its Isosorbide Mononitrate Tablet USP, available in 10 mg and 20 mg dosages. This launch emphasizes the company's commitment to providing high-quality, limited-competition products. ANI's CEO highlighted the importance of this approval in reinforcing their R&D capabilities and operational execution.
Read more →ANIPANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
ANI Pharmaceuticals announced the publication of the NEW DAY clinical trial results for ILUVIEN, a treatment for diabetic macular edema, in the journal Ophthalmology. The trial demonstrated ILUVIEN's efficacy, and the publication underscores ANI's commitment to advancing care for patients with this condition. However, safety information highlights potential risks associated with the treatment.
Read more →ANIPANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
ANI Pharmaceuticals reported record financial results for Q4 and full year 2025, with net revenues of $247.1 million and $883.4 million, respectively. The Rare Disease segment saw substantial growth, particularly with Cortrophin Gel, which is expected to drive future revenue. The company reaffirmed its financial guidance for 2026, anticipating over $1 billion in revenue, with a focus on expanding its Rare Disease business.
Read more →ANIPA NI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and
ANI Pharmaceuticals reported impressive financial results for the fourth quarter and full year 2025, with net revenues reaching $247.1 million and $883.4 million, respectively. The company experienced considerable growth in its Rare Disease portfolio, highlighted by a 50.8% increase in quarterly revenue. Despite the overall successes, ANI faced challenges with its brands segment, which saw a significant revenue decline during the same period. The company reaffirms its guidance for 2026, anticipating continued growth driven by Cortrophin Gel and strategic expansion in Rare Diseases.
Read more →ANIPANI Pharmaceuticals to Present at Upcoming Investor Conferences
ANI Pharmaceuticals announced that CEO Nikhil Lalwani and the executive team will present at upcoming investor conferences. The live and archived webcasts will be available on the company's website, ensuring accessibility for stakeholders. This initiative reflects the company's commitment to engaging with investors and promoting its diverse biopharmaceutical portfolio.
Read more →ANIPANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
ANI Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on February 27, 2026. The announcement will be followed by a conference call featuring key executives. The event will be accessible via the company's website, with a replay available for a year. ANI focuses on innovative therapeutics in various medical fields.
Read more →ANIP▲ +10.6%on this news
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP dilut
ANI Pharmaceuticals has reported significant growth for the year 2025, with an expected total net revenue between $854 million and $873 million. The company's Rare Disease business, particularly Cortrophin Gel, demonstrated exceptional performance, achieving a 76% increase in net revenues year-over-year. ANI also provided optimistic financial guidance for 2026, projecting revenues above $1 billion and a focus on expanding its operations in the Rare Disease sector, including a 90-person organizational increase. The company's strategic priorities aim to maximize growth and enhance patient care across several therapeutic areas.
Read more →ANIPANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise
ANI Pharmaceuticals has formed the FutureVision Advisory Council to strategically advance its ophthalmology and retina franchise. This council, co-led by prominent retina and uveitis specialists, aims to enhance growth strategies for existing products and develop new offerings. The initiative reflects ANI's dedication to serving patients and improving lives in the field of eye care.
Read more →ANIPANI Pharmaceuticals Announces Board Transition
ANI Pharmaceuticals announced a leadership transition as Patrick D. Walsh retires from his role as Chairman of the Board after a significant tenure. Thomas J. Haughey, a board member since 2018, has been elected as the new Chairman. The company is optimistic about its future growth, particularly in its Rare Disease business.
Read more →ANIPANI Pharmaceuticals Announces Board Transition Patrick D. Walsh steps down as Chairman and will complete his current term as Board member Thomas J. Haughey has been unanimously elected to serve as the next Chairman of th
ANI Pharmaceuticals announced a board transition as Patrick D. Walsh steps down as Chairman, completing his term through the 2026 Annual Meeting. Thomas J. Haughey has been unanimously elected as the new Chairman, highlighting his seven years of contribution as a Board member. Mr. Haughey expressed his commitment to supporting patients and driving profitable growth for shareholders. The transition reflects a planned leadership change at ANI aimed at continuing the company's business evolution.
Read more →ANIPANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London
ANI Pharmaceuticals announced that CEO Nikhil Lalwani will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18. The event will be accessible live and archived on the company's website for 90 days. ANI Pharmaceuticals focuses on developing innovative therapeutics across various medical fields.
Read more →ANIPANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
ANI Pharmaceuticals reported record financial results for Q3 2025, with total net revenues reaching $227.8 million, a 53.6% increase year-over-year. The Rare Disease segment, particularly Cortrophin Gel, saw exceptional growth, contributing significantly to overall revenues. The company has raised its 2025 financial guidance, anticipating a year-over-year revenue growth of 39% to 42%. ANI remains focused on expanding its Rare Disease business to enhance shareholder value.
Read more →ANIPANI Pharmaceuticals Reports Record Third Qu arter 2025 Financial Results and Raises 2025 Guidance Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortro
ANI Pharmaceuticals reported record financial results for the third quarter of 2025, showcasing a 53.6% year-over-year increase in total net revenues, reaching $227.8 million. The growth was notably driven by their Rare Disease segment, particularly Purified Cortrophin Gel, which saw a substantial revenue rise of 93.8%. This encouraging performance led the company to raise its financial guidance for 2025, expecting total net revenues of between $854.0 million and $873.0 million. However, the company faced challenges with ILUVIEN net revenues due to reduced access for Medicare patients, posing potential risks to future financial results.
Read more →ANIPANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
ANI Pharmaceuticals will announce its third quarter 2025 financial results on November 7, 2025. The announcement will be followed by a conference call featuring key executives to discuss the results. A replay of the call will be available for two weeks. The company emphasizes its commitment to developing innovative therapeutics.
Read more →ANIPANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
ANI Pharmaceuticals announced that results from the NEW DAY clinical trial of ILUVIEN for diabetic macular edema will be presented at the AAO 2025 Meeting. The late-breaking oral presentation will take place on October 17, 2025, by Dr. Victor H. Gonzalez. This event represents a significant opportunity for ANI to engage with the ophthalmology community regarding their findings.
Read more →ANIP▲ +18.1%on this news· ran to +29% by day 3
ANI Pharmaceuticals Reports Record Second Qu arter 2025 Financial Results and Raises 2025 Guidance Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53
ANI Pharmaceuticals reported record financial results for the second quarter of 2025, announcing net revenues of $211.4 million, a year-over-year increase of 53.1%. The company's Rare Disease segment, particularly through Cortrophin Gel, demonstrated exceptional growth, contributing significantly to overall revenue. ANI has raised its guidance for the full year 2025 in anticipation of sustained demand and growth. This reflects strong performance across its Generics business and a recovery in demand for certain branded products.
Read more →ANIPANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
ANI Pharmaceuticals announced results from the NEW DAY clinical trial evaluating ILUVIEN for diabetic macular edema (DME). While the primary endpoint of reducing supplemental aflibercept injections was not statistically significant, secondary endpoints showed promising results, including a significant increase in time to the first supplemental injection. The trial demonstrated ILUVIEN's potential to alleviate treatment burden for patients with DME.
Read more →ANIPnewdayinvestor NEW DAY Clinical Trial Results
The NEW DAY clinical trial results were presented, showcasing ILUVIEN as a promising treatment option for Diabetic Macular Edema (DME) patients. These findings indicate that ILUVIEN could benefit those who have not responded well to existing anti-VEGF therapies. However, the company cautions that there are risks associated with forward-looking statements and potential production disruptions due to supply chain dependencies.
Read more →ANIPANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN for Use in Patients with Diabetic Macular Edema (DME) Trial evaluated number of supplemental injections needed for the tr
ANI Pharmaceuticals announced the results from its NEW DAY clinical trial evaluating ILUVIEN for diabetic macular edema (DME) patients. Although the primary endpoint was not met, secondary results indicated that ILUVIEN may reduce treatment burden by extending the time to first supplemental injection compared to aflibercept. The trial included 306 treatment-naive patients over 18 months, and despite some adverse events, ILUVIEN was well tolerated, further supporting its role in DME treatment.
Read more →ANIPANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
ANI Pharmaceuticals is set to participate in the Leerink Partners Therapeutics Forum on July 8, 2025. CEO Nikhil Lalwani will host one-on-one meetings at the event in Boston, MA. This participation underscores ANI's commitment to engaging with investors and showcasing its diverse biopharmaceutical portfolio.
Read more →ANIPANI Pharmaceuticals Announces Presentation of New Preclinical Data
ANI Pharmaceuticals announced promising preclinical data for Cortrophin Gel, demonstrating its effectiveness in reducing joint swelling and inflammatory responses in a mouse model of collagen-induced arthritis. The study, presented at the EULAR 2025 Congress, highlights the drug's potential without causing adverse effects on bone turnover. This research underscores ANI's commitment to advancing treatment options for patients.
Read more →ANIP▼ -7.3%on this news
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4
ANI Pharmaceuticals reported record financial results for Q1 2025, with net revenues of $197.1 million, a 43.4% increase from the previous year. The company's Rare Disease products, especially Cortrophin Gel, showed strong performance, driving significant revenue growth. However, the retina products ILUVIEN and YUTIQ faced challenges due to market access issues and sales team transitions. Following this strong quarter, ANI has raised its revenue guidance for the year.
Read more →ANIPDocument ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN and
ANI Pharmaceuticals has completed the buyout of a 3.125% perpetual royalty obligation to SWK Funding LLC for $17.25 million. This strategic decision is aimed at enhancing their financial flexibility and focusing on the long-term value of their Retina portfolio, which includes ILUVIEN and YUTIQ. The company believes this move will accelerate growth and support their mission of serving patients and improving lives. The payment was funded using cash on hand, indicating the company's strong liquidity position.
Read more →ANIPDocument ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN Label ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition
ANI Pharmaceuticals has received FDA approval for the expanded label of ILUVIEN, which now includes treatment for chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The company intends to begin marketing ILUVIEN with the new indication in the U.S. later this year. This approval comes alongside updates to the warning and precaution sections of the label and reflects ANI's ongoing commitment to enhancing patient care. The product is already available for similar indications in various international markets.
Read more →ANIP▲ +13.4%on this news
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance Generated record quarterly net revenues of $190.6 million, representing year-over-year
ANI Pharmaceuticals has reported record financial results for the fourth quarter and full year of 2024, achieving total net revenues of $190.6 million, a 44.8% increase compared to the prior year. The company's Rare Disease segment generated significant revenues, particularly from Cortrophin Gel, which saw substantial growth. Following a transformative year marked by the acquisition of Alimera Sciences, ANI raised its guidance for 2025, anticipating continued growth in both net revenues and adjusted EBITDA. The company is optimistic about the future, particularly for the Rare Disease and generic segments of its business.
Read more →ANIPinvestordeck20 2025 ANI Pharmaceuticals, Inc. 1 Guggenheim SMID Cap Biotech Conference
ANI Pharmaceuticals, Inc. presented at the Guggenheim SMID Cap Biotech Conference, discussing forward-looking statements regarding its future operations. The company highlighted its focus on Cortrophin Gel, as well as its recent acquisition of Alimera Sciences. However, projections are tempered by potential challenges, including supply chain dependencies and regulatory hurdles that may affect product commercialization and profitability. The presentation emphasizes the inherent uncertainties and risks associated with the company's future performance.
Read more →ANIPANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA,
ANI Pharmaceuticals provided its preliminary financial results for the fourth quarter and full year 2024, along with an outlook for 2025. The company anticipates strong revenue figures, primarily driven by the Rare Disease segment, with estimated revenues of $739 million to $759 million in 2025. Additionally, ANI affirmed its previous guidance for 2024, indicating stability and positive momentum for the business. CEO Nikhil Lalwani expressed optimism regarding the company's future growth and performance in the upcoming J.P. Morgan Healthcare Conference.
Read more →ANIPinvestordeck11 2024 ANI Pharmaceuticals, Inc. 1 Jefferies Healthcare Conference
ANI Pharmaceuticals, Inc. presented at the 2024 Jefferies Healthcare Conference, highlighting its forward-looking statements regarding business expectations, particularly in relation to their product Cortrophin Gel. The presentation emphasized both potential commercialization challenges and operational performance metrics such as adjusted non-GAAP EBITDA. However, it acknowledged significant risks including reliance on third-party manufacturing, regulatory hurdles, and supply chain issues that could impact the company's financial situation and market strategies.
Read more →ANIP▲ +5.2%on this news
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Res ults and Raises 2024 Guidance Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.
ANI Pharmaceuticals reported a record net revenue of $148.3 million for Q3 2024, marking a 12.5% increase year-over-year, attributed largely to a 76.8% growth in Purified Cortrophin Gel sales. The company also completed the acquisition of Alimera Sciences, adding valuable assets to its Rare Disease portfolio. Despite these successes, ANI recorded a net loss of $(24.2) million amid rising operational costs. The company has raised its 2024 financial guidance in response to its strong performance and ongoing momentum.
Read more →ANIPDocument UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On
ANI Pharmaceuticals has finalized its acquisition of Alimera Sciences, making Alimera a wholly owned subsidiary. Each Alimera share will convert into a combination of cash and contingent value rights for future milestone payments. The deal is designed to strengthen ANI's financial resources as they move forward after the merger.
Read more →ANIPDocument FOR IMMEDIATE RELEASE ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on
ANI Pharmaceuticals, Inc. has completed its acquisition of Alimera Sciences, enhancing its Rare Disease segment and projecting an additional $105 million in revenue for 2024. The company aims to leverage the durable assets ILUVIEN and YUTIQ, expanding its presence in ophthalmology. This transaction is also expected to provide substantial shareholder value through significant EPS accretion in the coming years. ANI maintains its 2024 guidance despite the acquisition, showcasing confidence in its ongoing business momentum.
Read more →ANIPANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers' Option to Purchase Additional Notes PRINCETON, N.J.
ANI Pharmaceuticals, Inc. has announced the closing of its $316.25 million convertible senior notes offering, increased from its initial offering amount due to high investor interest. The notes are set to mature in 2029, and the company plans to use a portion of the proceeds to fund capped call transactions while the remainder will repay existing debt. The successful upsizing and execution of this offering suggest positive market confidence in ANI's future performance and financial stability.
Read more →ANIP▼ -9.9%on this news
ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering PRINCETON, N.J.
ANI Pharmaceuticals, Inc. announced the pricing of its increased offering of $275 million in convertible senior notes due 2029. The offering, which is aimed at qualified institutional buyers, saw an increase from the previously announced $250 million and will settle on August 13, 2024. Proceeds from the offering will primarily be used to repay existing debt and cover costs related to capped call transactions. The initial conversion price represents a 30% premium over the current stock price, giving noteholders potential upside if the stock performs well.
Read more →ANIP▼ -9.9%on this news
ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering PRINCETON, N.J.
ANI Pharmaceuticals, Inc. has announced its intention to offer $250 million in convertible senior notes as part of a private offering aimed at qualified institutional buyers. The notes will mature in 2029 and will be used primarily to repay existing debt and fund capped call transactions. The offering reflects ANI's strategy to enhance its financial position while aiming for future growth in the biopharmaceutical sector. The terms of the notes are determined based on market conditions, with potential adjustments based on the company's stock performance.
Read more →ANIP▲ +7%on this newsshared move
ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4% , an
ANI Pharmaceuticals reported strong financial results for Q2 2024, achieving record net revenues of $138.0 million, a year-over-year growth of 18.4%. The company also raised its guidance for the full year, anticipating net revenues between $540 million and $560 million, buoyed by strength in its Rare Disease segment. However, ANI reported a net loss of $2.7 million and a decrease in adjusted diluted earnings per share. With the forthcoming acquisition of Alimera Sciences, ANI aims to enhance its product offerings and market reach.
Read more →ANIP▲ +7.3%on this news
Document FOR IMMEDIATE RELEASE ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8 30 a.m. ET Strengthens Rare Disease segment as l
ANI Pharmaceuticals has announced its acquisition of Alimera Sciences for $5.50 per share, expected to close by late Q3 2024. This acquisition will enhance ANI's Rare Disease business, projected to contribute around $105 million in revenue and achieve substantial growth in the ophthalmology sector through the integration of Alimera's commercial assets, ILUVIEN and YUTIQ. The deal is anticipated to drive significant shareholder value by increasing adjusted non-GAAP EPS in 2025 and leveraging cost synergies. Additionally, ANI will enhance its global footprint with Alimera's operations in various international markets.
Read more →ANIPinvestordeckju 2024 ANI Pharmaceuticals, Inc. 1 June 2024 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forward
ANI Pharmaceuticals, Inc. presented its outlook for 2024, highlighting its focus on rare disease treatments and generics as primary growth drivers. The company reports strong financials, including a significant increase in revenue and adjusted non-GAAP EBITDA. Despite positive growth, ANI also acknowledges risks associated with commercializing its lead product, Cortrophin Gel, as well as potential regulatory hurdles and supply chain vulnerabilities. Future success will heavily depend on the company's ability to navigate these challenges while fostering growth in its diverse product pipeline.
Read more →ANIPinvestordeckma 2024 ANI Pharmaceuticals, Inc. 1 Capital One 1st Annual Biotech/Biopharma Disruptors Event
ANI Pharmaceuticals, Inc. discussed its outlook for growth during the 1st Annual Biotech/Biopharma Disruptors Event. The company identified its Rare Disease business, particularly the lead asset Purified Cortrophin Gel, as a key growth driver. Future revenue is projected to increase significantly, with rare disease revenues estimated between $170 million and $180 million in 2024. However, challenges remain, including market acceptance of products and risks associated with supplier dependencies.
Read more →ANIPANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of
ANI Pharmaceuticals reported record financial results for the first quarter of 2024, achieving net revenues of $137.4 million, a 28.7% increase from the previous year. The company's Rare Disease segment led the growth, with revenues from Cortrophin Gel rising 126.2%. ANI reiterated its 2024 guidance, projecting net revenues between $520 million and $542 million. Despite the positive results, increased operating and R&D expenses raised concerns about cost management going forward.
Read more →ANIPinvestordeckap 2024 ANI Pharmaceuticals, Inc. 1 April 2024 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forwar
ANI Pharmaceuticals, Inc. has reported a strong performance in Q4 2023, capping off a record year with a 54% revenue growth and an adjusted EBITDA increase of 140%. The company's growth is primarily attributed to its Rare Disease business and Generics segment. However, several risks have been highlighted, including the company's dependence on the successful commercialization of Cortrophin Gel and potential supply chain disruptions. Overall, the company aims to expand its market presence while facing competitive and regulatory challenges.
Read more →ANIP▲ +12.3%on this news
ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance Generated quarterly net revenues of $131.7 million, representing year-over-year grow
ANI Pharmaceuticals announced its financial results for Q4 and the full year 2023, reporting significant growth in net revenues and adjusted EBITDA. The company generated $131.7 million in revenue for the quarter, fueled largely by its Rare Disease business, particularly the Cortrophin Gel product which saw a year-over-year increase in sales. Looking ahead, ANI expects continued growth in 2024, with guidance indicating net revenues of $520 million to $542 million. However, the company also noted rising operating expenses and an anticipated decrease in adjusted earnings per share compared to 2023.
Read more →ANIP▲ +12.3%on this news
20240312 2024 ANI Pharmaceuticals, Inc. 1 March 2024 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forward-look
ANI Pharmaceuticals released a forward-looking statement discussing its projections and the current state of its business. The company reported strong financial performance in 2023, highlighted by a 54% increase in revenue and impressive growth in Adjusted non-GAAP EBITDA. However, it acknowledges various challenges, including risks associated with the commercialization of its lead product, Cortrophin Gel, and potential supply chain disruptions that could affect operations. The company also faces uncertainties related to FDA approvals and competition in the pharmaceutical market.
Read more →ANIPinvestordeckja 2023 ANI Pharmaceuticals, Inc. 1 January 2024 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc ("ANI" or the "Company") contains forward-looking statements, includi
ANI Pharmaceuticals, Inc. showcased significant growth in its recent presentation, highlighting a 49.5% revenue increase year-over-year for 2023. Q3 2023 marked record financial results, with total revenues reaching $132 million and a notable performance from the lead product, Cortrophin Gel, which experienced a 136% rise in revenue. However, the company also acknowledged various risks, including dependence on single source suppliers and potential delays in FDA approvals, which could impact future operations.
Read more →ANIPinvestordeckno 2023 ANI Pharmaceuticals, Inc. 1 Jefferies London Healthcare Conference November 2023 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc ("ANI" or the "Company") cont
ANI Pharmaceuticals, Inc. presented at the Jefferies London Healthcare Conference and reported robust financial performance for Q3 2023. The company achieved revenues of $132 million, reflecting a 57% increase year-over-year. Key growth was driven by their Rare Disease business, particularly the Purified Cortrophin Gel asset. ANI also raised its guidance for full-year 2023 for the third consecutive quarter, highlighting strong momentum in new product launches and operational improvements amidst industry challenges.
Read more →ANIP▼ -14.6%on this news
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, re
ANI Pharmaceuticals announced its financial results for the third quarter of 2023, reporting record net revenues of $131.8 million, a 57.3% increase year-over-year. The company raised its full-year guidance for revenue and EBITDA based on strong sales performance, particularly from its lead asset, Cortrophin Gel, which saw significant growth. ANI also reported a record number of new patient initiations and increasing interest from new prescribers. However, the company noted potential demand softening in certain products going into the fourth quarter.
Read more →ANIPpressrelease10 For Immediate Release ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin Gel, Appropriate for Adjunctive Treatment of Certain Patients with
ANI Pharmaceuticals has announced the FDA approval and commercial availability of a new 1-mL vial size of Purified Cortrophin Gel, aimed at treating acute gouty arthritis flares. This product is the only FDA-approved corticotropin therapy for this indication. The 1-mL size is designed to facilitate quicker administration in healthcare settings and expands the Cortrophin Gel product line, which previously included a 5-mL vial. The company's initiative aims to increase accessibility for over 9 million gout patients in the U.S.
Read more →ANIPinvestorpresen 2023 ANI Pharmaceuticals, Inc. 1 Investor Presentation September 2023 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc ("ANI" or the "Company") contains forward-loo
ANI Pharmaceuticals, Inc. presented optimistic forward-looking statements in its recent investor presentation, highlighting strong growth in revenue and adjusted EBITDA for the first half of 2023. The company has successfully launched Purified Cortrophin Gel, resulting in increased new patient starts and prescribers. Additionally, ANI has raised its revenue guidance for fiscal year 2023 for the second consecutive quarter, indicating confidence in ongoing business momentum. The company's rare disease platform is viewed as a significant driver for future growth.
Read more →ANIPANI Pharmaceuticals, Inc. 1 2023 ANI Pharmaceuticals, Inc. 1 Investor Presentation August 2023 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc ("ANI" or the "Company") contains f
ANI Pharmaceuticals, Inc. recently conducted an investor presentation highlighting its strong financial performance and strategic plans for growth. The company reported record revenues and Adjusted Non-GAAP EBITDA in the first and second quarters of 2023 and raised its full-year guidance for upcoming results. Key growth drivers include the momentum from its Purified Cortrophin Gel product, alongside efforts to leverage its rare disease platform. However, the company cautions investors about the inherent risks associated with forward-looking statements.
Read more →ANIPANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors -- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has signif
ANI Pharmaceuticals has appointed Matthew J. Leonard to its Board of Directors, effective immediately. Mr. Leonard brings over 35 years of experience in the pharmaceutical industry, including roles in pharmacy benefits management and specialty pharmacy. His experience is expected to assist ANI in expanding its Rare Disease business, a key growth area. The company has recently experienced a record quarter, highlighting its positive trajectory.
Read more →ANIP▲ +9.2%on this news
ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million,
ANI Pharmaceuticals reported record financial results for Q2 2023, with net revenues reaching $116.5 million and a significant increase in adjusted non-GAAP EBITDA to $34.1 million. The company raised its full-year revenue guidance to between $425 million and $445 million, reflecting strong growth across various segments, particularly in its Rare Disease portfolio. Notably, sales for its lead asset, Cortrophin Gel, grew by 138.2%, driven by increasing patient demand and new prescriber activity. The robust performance reflects ANI's operational excellence and strategic focus on expanding business opportunities.
Read more →ANIPANI Pharmaceuticals, Inc. 1 2023 ANI Pharmaceuticals, Inc. 1 Jefferies Healthcare Conference June 2023 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc ("ANI" or the "Company") co
ANI Pharmaceuticals, Inc. presented a robust outlook during the Jefferies Healthcare Conference in June 2023, highlighting impressive financial metrics, such as record quarterly revenues and adjusted EBITDA for Q1 2023. A primary focus was the successful launch and growth of Purified Cortrophin Gel, which is enhancing their Rare Disease business. The company noted ongoing success in the generics sector, attributed to strong product approval rates and improvements in supply chain reliability. Overall, ANI appears well-positioned for sustainable growth in the biopharmaceutical landscape.
Read more →ANIP▲ +8.3%on this news
ANI PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES BAUDETTE, Minn.- (BUSINESS WIRE)
ANI Pharmaceuticals, Inc. announced the successful closing of its underwritten public offering, selling 2,183,545 shares of common stock at a price of $39.50 per share. This includes the full exercise of underwriters' option to purchase an additional 284,810 shares. The total gross proceeds from this offering amount to around $86.25 million, which will be beneficial for the company's future initiatives.
Read more →ANIP▼ -5.2%on this newsshared move
ANI PHARMACEUTICALS ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING OF COMMON STOCK BAUDETTE, Minn.-- (BUSINESS WIRE)
ANI Pharmaceuticals announced the pricing of a public offering of 1,898,735 shares at $39.50 each, aiming to raise approximately $75 million. The offering is expected to close around May 16, 2023, pending standard closing conditions. The company has granted underwriters a 30-day option to buy additional shares, reflecting confidence in market demand. However, market conditions may pose risks to the successful closing of the offering.
Read more →ANIPANI PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK BAUDETTE, Minn.-- (BUSINESS WIRE)
ANI Pharmaceuticals announced a proposed public offering of common stock, aiming to raise capital for various business opportunities and commercialization efforts. The stock offering will entirely consist of shares offered by ANI and is dependent on market conditions, with no guarantees regarding its completion or specific terms. The company plans to utilize the net proceeds for in-licensing and acquisition purposes, as well as general corporate expenses. The announcement comes amid the company's ongoing focus on growth and expansion of its product portfolio.
Read more →ANIP▲ +8.8%on this newsshared move
ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance First Quarter 2023 Financial Results -- Record quarterly net revenues of $106.8 million, re
ANI Pharmaceuticals announced its first quarter 2023 financial results, highlighting a record net revenue of $106.8 million, which is a year-over-year increase of 65.6%. The company also raised its full-year guidance for net revenue and adjusted non-GAAP EBITDA, demonstrating confidence in ongoing growth. Sales of Cortrophin Gel reached $16.3 million during the quarter, with strong momentum indicated by record new patient starts. Furthermore, ANI retained a top ranking for new ANDA approvals, reinforcing its competitive position in the market.
Read more →ANIPANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance Fourth Quarter and Full Year 2022 Financial Results -- Q4 n
ANI Pharmaceuticals reported record fourth quarter results and significant revenue milestones for the full year 2022. Total net revenues reached $316.4 million, despite a reported net loss of $49.5 million. The company has provided optimistic guidance for 2023, projecting revenues between $360 million and $385 million, driven in part by anticipated growth from their rare disease asset, Cortrophin Gel. The generics segment also showed strong performance with a 39.4% year-over-year increase in sales. However, concerns remain due to a decline in established brand revenue and rising operating costs.
Read more →ANIP▼ -9.2%on this news
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues Third Quarter 2022 Results: -- Net revenues of $83.8 million, net loss available to common shareholders
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues Third Quarter 2022 Results: Net revenues of $83.8 million, net loss available to common shareholders of $(9.0) million and diluted GAAP loss per share of $(0.55) Adjusted non-GAAP EB
Read more →ANIP▼ -9.2%on this news
ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. Judy DiClemente; ANI Pharmaceuticals, Inc.; Investor Relations Nikhil Lalwani; ANI Pharmaceuticals, Inc.; President and Chief Executive Officer Steven Carey; ANI Pharmaceuticals, Inc.; Chief Financial Officer Christopher Mutz; ANI Pharmaceutical
Read more →ANIPANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin Gel Second Quarter 2022 Results: -- Net revenues of $7
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin Gel Second Quarter 2022 Results: -- Net revenues of $73.9 million, net loss available to common shareholders o
Read more →ANIPANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition -- Operations at Oakville, Canada manufacturing plant expected to end
Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition at Oakville, Canada manufacturing plant expected to end by first quarter 2023 -- of ongoing efforts to drive cost-competitiveness and deliver sustainable growth for ge
Read more →ANIPANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors - Dr. Tannenbaum's successful track record in driving commercial excellence to contribute as Company e
Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors successful track record in driving commercial excellence to contribute as Company executes Purified Cortrophin GelTM BAUDETTE, Minn., March 22, 2022 - ANI Pharmaceuticals, Inc. (N
Read more →ANIP▼ -18.6%on this news
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth -- Fourth quarter net revenues of $60.9 million; net loss of $24.1 million and diluted loss pe
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth -- Fourth quarter net revenues of $60.9 million; net loss of $24.1 million and diluted loss per share of $1.72 -- -- Fourth quarter adjusted non-GAAP
Read more →ANIPANI Pharmaceuticals, Inc. 210 Main Street West Baudette, MN 56623 https://www.anipharmaceuticals.com ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin Gel (Repository Corticotropin Injection US
Pharmaceuticals, Inc. 210 Main Street West https://www.anipharmaceuticals.com Pharmaceuticals Announces Commercial Availability of Purified Cortrophin Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders Minn., January 24, 2022 - ANI Pharma
Read more →ANIPANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses -- Combined company creates generics growth engine wi
Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost e
Read more →ANIPANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock Baudette, Minnesota
ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock Baudette, Minnesota, November 3, 2021-ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) ("ANI") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Read more →ANIP▲ +49.5%on this newsshared move
ANI Pharmaceuticals Reports Third Quarter 2021 Results -- Third quarter 2021 net revenues of $52.1 million; net loss of $4.4 million and diluted loss per share of ($0.37) -- -- Third quarter adjuste
Pharmaceuticals Reports Third Quarter 2021 Results Third quarter 2021 net revenues of $52.1 million; net loss of $4.4 million and diluted loss per share of ($0.37) -- Third quarter adjusted non-GAAP EBITDA of $16.6 million and adjusted non-GAAP diluted earnings per share of $1.
Read more →ANIPANI Pharmaceuticals Reports Second Quarter 2021 Results -- Second quarter 2021 net revenues of $48.6 million; net loss of $14.1 million and diluted loss per share of ($1.17) -- -- Second quarter adj
Reports Second Quarter 2021 Results 2021 net revenues of $48.6 million; net loss of $14.1 million and diluted loss per share of ($1.17) -- adjusted non-GAAP EBITDA of $13.1 million and adjusted non-GAAP diluted earnings per share of $0.67 -- Refiled supplemental new drug appli
Read more →ANIPANI Pharmaceuticals, Inc. 1 2021 ANI Pharmaceuticals, Inc. 1 Jefferies Healthcare Conference June 2021 Jefferies Healthcare Conference 2021 ANI Pharmaceuticals, Inc. 2 Disclaimer Cautionary Note Regarding Forward - Looki
2021 ANI Pharmaceuticals, Inc. 1 2021 ANI Pharmaceuticals, Inc. 1 Jefferies Healthcare Conference June 2021 Jefferies Healthcare Conference 2021 ANI Pharmaceuticals, Inc. 2 Disclaimer Cautionary Note Regarding Forward - Looking Statements This presentation contemplates the acqui
Read more →ANIPANI Pharmaceuticals Reports First Quarter 2021 Results -- First quarter 2021 net revenues of $54.5 million; net income of $0.1 million and diluted earnings per share of $0.01 -- -- First quarter adj
Pharmaceuticals Reports First Quarter 2021 Results -- First quarter 2021 net revenues of $54.5 million; net income of $0.1 million and diluted earnings per share of $0.01 -- -- First quarter adjusted non-GAAP EBITDA of $18.9 million and adjusted non-GAAP diluted earnings per
Read more →ANIPANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs -- Accretive transaction in line with growth strategy laid out for Branded Products business -- Baudett
ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs -- Accretive transaction in line with growth strategy laid out for Branded Products business -- Minnesota (April 6, 2021) - ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ:ANIP) today ann
Read more →ANIPANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth -- Fourth quarter 2020 net revenues of $57.3 million; net loss of $3.6 million
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth -- Fourth quarter 2020 net revenues of $57.3 million; net loss of $3.6 million and diluted loss per share of $0.30 -- -- Fourth quarter adjusted non-GAAP EB
Read more →ANIPANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business Creates Sustainable Generics Growth Engine with Approximately 25+ Launches Expected
ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business Minnesota (March 9, 2021) - ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire
Read more →ANIPAbout ANI ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product dev
Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormone
Read more →ANIPThe field allows up to 17 characters.
The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei_EntityFileNum
Read more →ANIPANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio "Tony" Pera to Board of Directors Additions reflect ANI's commitment to broaden pharmaceutical industry e
ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio "Tony" Pera to Board of Directors Additions reflect ANI's commitment to broaden pharmaceutical industry experience on Board BAUDETTE, Minn., August 6, 2020 - ANI Pharmaceuticals, Inc
Read more →ANIPANI Pharmaceuticals Reports Second Quarter 2020 Results - Second quarter 2020 net revenues of $48.5 million - - Nikhil Lalwani named President and CEO, effective
ANI Pharmaceuticals Reports Second Quarter - Second quarter 2020 net revenues of - Nikhil Lalwani named President and CEO, effective - Pharmaceutical industry executives, Jeanne Thoma and Tony Pera, join Board of Directors - Baudette, Minnesota (August 6, 2020) - ANI Pharmac
Read more →ANIPANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive Officer -Accomplished leader with proven record of achievement to drive next phase of Company's growth
ANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive Officer -Accomplished leader with proven record of achievement to drive next phase of Company's growth- BAUDETTE, Minn., August 3, 2020 - ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANI
Read more →ANIPANI Pharmaceuticals Provides Update on Recent Regulatory Filing Baudette, Minnesota (
ANI Pharmaceuticals Provides Update on Recent Regulatory Baudette, Minnesota (June 1, 2020) - ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) announced today that it continues to make progress toward addressing items identified in the Refusal to File letter received from the
Read more →ANIPANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO For the first quarter 2020, ANI reports: Net revenues of $49.8 million versus $52.9 million in 2019 GAAP net loss of $7.0 million and dilute
ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO For the first quarter 2020, ANI reports: Integrates Amerigen Pharmaceuticals, Ltd. portfolio Launches five generic products increasing total commercialized product line to 60 product families Ap
Read more →ANIPNASDAQ: ANIP ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2020 Financial Results BAUDETTE, Minnesota (
ANI Pharmaceuticals Schedules Conference First Quarter 2020 Financial Results BAUDETTE, Minnesota (April 30, 2020) - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2020 financial results on Thursday, May 7, 2020, b
Read more →ANIPANI Receives Refusal to File Letter from FDA for Cortrophin Gel BAUDETTE, Minnesota (
ANI Receives Refusal to File Letter from FDA for Cortrophin BAUDETTE, Minnesota (April 29, 2020) - ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its su
Read more →ANIPANI Announces Upcoming Departure of CEO BAUDETTE, Minnesota (
ANI Announces Upcoming Departure of Minnesota (April 14, 2020) - ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that Arthur S. Przybyl will depart as President and Chief Executive Officer on May 10 , 2020. The Board of Directors has retained a nationally reco
Read more →ANIPANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin Gel sNDA to FDA in March 2020 For the full year ended
ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin Gel sNDA to FDA in March 2020 For the full year ended December 31, 2019: For the fourth quarter 2019: Baudette, Minnesota (February 27, 2020
Read more →ANIPNASDAQ: ANIP ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2019 Financial Results BAUDETTE, Minnesota (
ANI Pharmaceuticals Schedules Conference Fourth Quarter and Year-to-Date 2019 BAUDETTE, Minnesota (February 20, 2020) - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and year-to-date 2019 financial results on Thu
Read more →ANIPANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd. BAUDETTE, Minnesota (
ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd. BAUDETTE, Minnesota (January 9, 2020) - ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of the U.S. portfolio of 23 generi
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation December 2019
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation December 2019 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward
Read more →ANIPANI Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference BAUDETTE, Minnesota (
ANI Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference BAUDETTE, Minnesota (November 26, 2019) - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on December 3, 2019 at the Evercore ISI HealthCONx Conference in Boston, Massachusetts. Arthur Przybyl,
Read more →ANIPANI Pharmaceuticals Reports Third Quarter Results For the third quarter 2019: Net revenues of $51.3 million, an increase of 1% versus prior year GAAP net income of $3.9 million and diluted GAAP earnings per share of $0.3
ANI Pharmaceuticals Reports Third Quarter Results For the third quarter 2019: Baudette, Minnesota (November 6, 2019) - ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported its financial results for the three and nine months ended September 30, 2019 and updated its
Read more →ANIPNASDAQ: ANIP ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2019 Financial Results BAUDETTE, Minnesota (
ANI Pharmaceuticals Schedules Conference Third Quarter and Year-to-Date 2019 BAUDETTE, Minnesota (October 30, 2019) - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2019 financial results on Wednes
Read more →ANIPANI Pharmaceuticals Reports Second Quarter Results
ANI Pharmaceuticals Reports Second Quarter Results BAUDETTE, Minn., Aug. 7, 2019 /PRNewswire/ -- For the second quarter 2019: Net revenues of $54.4 million, an increase of 15% versus prior year GAAP net income of $6.6 million and diluted GAAP earnings per share of $0.53, incr
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2019 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2019 Financial Results BAUDETTE, Minn., July 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-t
Read more →ANIPANI Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference
ANI Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference BAUDETTE, Minn., June 12, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on June 18, 2019 at Raymond James' Life Sciences and MedTech Conference in New York City. Art
Read more →ANIPANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance
ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance BAUDETTE, Minn., May 9, 2019 /PRNewswire/ -- For the first quarter 2019: Net revenues of $52.9 million, an increase of 14% versus 2018 GAAP net income of $0.4 million and diluted GAAP earnings per s
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2019 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2019 Financial Results BAUDETTE, Minn., May 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2019 financial results on Thurs
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation March 2019 Forward - Looking Statements To the extent any statements made in this presentation deal wi
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation March 2019 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward -
Read more →ANIPANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance
ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance BAUDETTE, Minn., Feb. 27, 2019 /PRNewswire/ -- For the full year ended December 31, 2018: Record net revenues of $201.6 million, an increase of 14% versus 2017 GAAP net inc
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2018 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2018 Financial Results BAUDETTE, Minn., Feb. 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and year-t
Read more →ANIPANI Pharmaceuticals Secures Refinancing for Convertible Debt Due December 2019 and Enters Amended Five-Year $265 Million Senior Secured Credit Facility
ANI Pharmaceuticals Secures Refinancing for Convertible Debt Due December 2019 and Enters Amended Five-Year $265 Million Senior Secured Credit Facility BAUDETTE, Minn., Dec. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) (Nasdaq: ANIP) today announced
Read more →ANIPANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance
ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance BAUDETTE, Minn., Nov. 6, 2018 /PRNewswire/ -- For the third quarter 2018: Record net revenues of $50.7 million, an increase of 5% as compared to the same period in 2017 GAAP net inc
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results BAUDETTE, Minn., Oct. 30, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-
Read more →ANIPEyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
EyePoint Pharmaceuticals has received FDA approval for YUTIQ™, a long-lasting treatment for chronic non-infectious posterior segment uveitis. The micro-insert offers continuous control for up to three years and has shown significant efficacy in clinical trials, although some adverse reactions were noted.
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2018 Forward - Looking Statements To the extent any statements made in this presentation deal w
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2018 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward -
Read more →ANIPANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance Acquires WellSpring Pharma Services for $18 Million in Cash to Expand Contract Manufacturing Business and Accelerate ANDA Pipe
ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance Acquires WellSpring Pharma Services for $18 Million in Cash to Expand Contract Manufacturing Business and Accelerate ANDA Pipeline Re-commercialization Efforts Targets sNDA Filing for
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results BAUDETTE, Minn., Aug. 1, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation May 2018 Forward - Looking Statements To the extent any statements made in this presentation deal with
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation May 2018 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - lo
Read more →ANIPANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance
ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance BAUDETTE, Minn., May 8, 2018 /PRNewswire/ -- For the first quarter 2018: Net revenues of $46.5 million, an increase of 27% as compared to the same period in 2017 GAAP net income of $2.3 million and
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results BAUDETTE, Minn., May 1, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2018 financial results on Tuesd
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation March 7, 2018 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward
Read more →ANIPANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance
ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance BAUDETTE, Minn., Feb. 27, 2018 /PRNewswire/ -- For the full year ended December 31, 2017: Record net revenues of $176.8 million, an increase of 37% versus 2016
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results and 2018 Guidance
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results and 2018 Guidance BAUDETTE, Minn., Feb. 20, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth qua
Read more →ANIPANI Pharmaceuticals Acquires Four NDAs from AstraZeneca for $46.5 Million
ANI Pharmaceuticals Acquires Four NDAs from AstraZeneca for $46.5 Million BAUDETTE, Minn., Dec. 29, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ( ANI ) (Nasdaq: ANIP) today announced that it has acquired the NDAs and U.S. rights to market ATACAND , ATACAND HCT , ARIMIDEX , an
Read more →ANIPANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance
ANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance BAUDETTE, Minn., Nov. 2, 2017 /PRNewswire/ -- For the third quarter 2017: Net revenues of $48.2 million, an increase of 25% as compared to the same period in 2016 GAA
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2017 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2017 Financial Results BAUDETTE, Minn., Oct. 26, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2017 Forward - Looking Statements To the extent any statements made in this presentation deal w
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2017 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward -
Read more →ANIPANI Pharmaceuticals Reports Record Second Quarter and Year-To-Date 2017 Results and Reaffirms Guidance
ANI Pharmaceuticals Reports Record Second Quarter and Year-To-Date 2017 Results and Reaffirms Guidance BAUDETTE, Minn., Aug. 3, 2017 /PRNewswire/ -- For the second quarter 2017: Net revenues of $44.8 million, an increase of 43% as compared to the same period in 2016 GAAP net
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2017 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2017 Financial Results BAUDETTE, Minn., July 27, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-t
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Investor Presentation June 20, 2017
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Investor Presentation June 20, 2017 2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forwar
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation June 2017
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation June 2017 2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward -
Read more →ANIPANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2017 Highlights and Reaffirms Guidance
ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2017 Highlights and Reaffirms Guidance BAUDETTE, Minn., May 4, 2017 /PRNewswire/ -- For the first quarter 2017: Net revenues of $36.6 million, an increase of 78% as compared to the same period in 2016 GAAP net
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2017 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2017 Financial Results BAUDETTE, Minn., April 27, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2017 financial results on Th
Read more →ANIPANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance
ANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance BAUDETTE, Minn., March 2, 2017 /PRNewswire/ -- For the full year ended December 31, 2016: Record net revenues of $128.6 million, an increase of 69% versus the prior year G
Read more →ANIPANI Pharmaceuticals Acquires Inderal XL and InnoPran
ANI Pharmaceuticals Acquires Inderal XL and InnoPran XL BAUDETTE, Minn., Feb. 24, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ( ANI ) (Nasdaq: ANIP) today announced that it has acquired Inderal XL from Cranford Pharmaceuticals, LLC and InnoPran XL from Holmdel Pharmaceuticals
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation March 2017 Forward - Looking Statements To the extent any statements made in this presentation deal wi
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation March 2017 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward -
Read more →ANIPANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2016 Financial Results and 2017 Guidance
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2016 Financial Results and 2017 Guidance BAUDETTE, Minn., Feb. 16, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter an
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation November 2016 Forward - Looking Statements To the extent any statements made in this presentation deal
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation November 2016 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward
Read more →ANIPEXHBIT 99.1 ANI Pharmaceuticals Reports Record Third Quarter Results and Year-To-Date 2016 Highlights and Narrows Full-year Guidance For the third quarter 2016: - Record net revenues of $38.5 million, an increase of 93%
ANI Pharmaceuticals Reports Record Third Quarter Results and Year-To-Date 2016 Highlights and Narrows Full-year Guidance For the third quarter 2016: - Record net revenues of $38.5 million, an increase of 93% as compared to the same period in 2015 - GAAP net income of $2.5 mill
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2016 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2016 Financial Results BAUDETTE, Minn., Oct. 27, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2016
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2016 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward -
Read more →ANIPANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full-year 2016 Guidance For the second quarter 2016: - Record net revenues of $31.3 million, an increase of 61% as compared to the same period in 20
ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full-year 2016 Guidance For the second quarter 2016: - Record net revenues of $31.3 million, an increase of 61% as compared to the same period in 2015 - GAAP net income of $1.1 million and diluted GAAP ear
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2016 Forward - Looking Statements To the extent any statements made in this presentation deal w
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2016 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward -
Read more →ANIPANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2016 Financial Results
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2016 Financial Results BAUDETTE, Minn., July 28, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-t
Read more →ANIPANI Pharmaceuticals to Present at the UBS Global Healthcare Conference
ANI Pharmaceuticals to Present at the UBS Global Healthcare Conference BAUDETTE, Minn., May 18, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on May 23, 2016 at the UBS Global Healthcare Conference at the Grand Hyatt in New Yo
Read more →ANIPANI Pharmaceuticals Enters Three Year $30 Million Asset Based Line of Credit with Citizens Bank
ANI Pharmaceuticals Enters Three Year $30 Million Asset Based Line of Credit with Citizens Bank BAUDETTE, Minnesota, May 13, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ( ANI ) (Nasdaq: ANIP) today announced that it has entered a new three year senior secured asset-based revo
Read more →ANIPANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2016 Highlights and Reaffirms Updated Guidance For the first quarter 2016: - Net revenues of $20.6 million, adjusted non-GAAP EBITDA of $11.4 million, an
ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2016 Highlights and Reaffirms Updated Guidance For the first quarter 2016: - Net revenues of $20.6 million, adjusted non-GAAP EBITDA of $11.4 million, and operating income of $5.7 million - Adjusted non-GAAP ne
Read more →ANIPANI Announces Appointment of Stephen P. Carey as Vice President and Chief Financial Officer BAUDETTE, Minnesota (
ANI Announces Appointment of Stephen P. Carey as Vice President and Chief Financial Officer BAUDETTE, Minnesota (April 27, 2016) - ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Stephen P. Carey to the position of Vice President and Chief
Read more →ANIPANI Pharmaceuticals Closes Acquisition of Inderal LA Assets
ANI Pharmaceuticals Closes Acquisition of Inderal LA Assets BAUDETTE, Minn., April 4, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ( ANI ) (Nasdaq: ANIP) today announced that it has completed the acquisition of the portfolio of Inderal LA assets from Cranford Pharmaceuticals,
Read more →ANIPANI Pharmaceuticals Agrees to Acquire Inderal LA Assets from Cranford Pharmaceuticals
ANI Pharmaceuticals Agrees to Acquire Inderal LA Assets from Cranford Pharmaceuticals BAUDETTE, Minn., March 11, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ( ANI ) (Nasdaq: ANIP) today announced that it has agreed to acquire a portfolio of Inderal LA assets from Cranford Pha
Read more →ANIPANI Pharmaceuticals to Present at 28th Annual ROTH Conference
ANI Pharmaceuticals to Present at 28th Annual ROTH Conference BAUDETTE, Minn., March 9, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present at the 28th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California. On Marc
Read more →ANIPANI Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results and Provides 2016 Guidance For the full year ended
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results and Provides 2016 Guidance For the full year ended December 31, 2015: - Net revenues of $76.3 million, adjusted non-GAAP EBITDA of $43.5 million, and operating income of $32.7 million, increases of 36%, 59%,
Read more →ANIPANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2015 Financial Results and 2016 Guidance
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2015 Financial Results and 2016 Guidance BAUDETTE, Minn., Feb. 16, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter an
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation January 2016 Forward - Looking Statements To the extent any statements made in this presentation deal
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation January 2016 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward
Read more →ANIPANI Pharmaceuticals Presents At Oppenheimer 26th Annual Healthcare Conference
ANI Pharmaceuticals Presents At Oppenheimer 26th Annual Healthcare Conference BAUDETTE, Minn., Dec. 8, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present today at the Oppenheimer & Co. 26th Annual Healthcare Conference at the Westin Grand Central Hotel in
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation November 2015
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation November 2015 2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forwa
Read more →ANIPANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2015 Results and Highlights For the third quarter 2015: - Net revenues of $20.0 million, an increase of 15% versus third quarter 2014 - Adjusted non-GAAP EBITDA
ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2015 Results and For the third quarter 2015: - Net revenues of $20.0 million, an increase of 15% versus third quarter 2014 - Adjusted non-GAAP EBITDA of $11.6 million and operating income of $8.5 million, increases of
Read more →ANIPANI Pharmaceuticals Schedules Conference Call for Third Quarter and Year-to-Date 2015 Financial Results
ANI Pharmaceuticals Schedules Conference Call for Third Quarter and Year-to-Date 2015 Financial Results BAUDETTE, Minn., Oct. 27, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 20
Read more →ANIPANI Pharmaceuticals Appoints Peter A. Lankau to Its Board of Directors
ANI Pharmaceuticals Appoints Peter A. Lankau to Its Board of Directors BAUDETTE, Minn., Oct. 13, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ( ANI ) (NASDAQ: ANIP) announced today the appointment of Peter A. Lankau to the Company's Board of Directors to fill the existing vaca
Read more →ANIPANI Pharmaceuticals to Acquire Two NDAs from Merck for $75 Million Transaction Highlights: - Corticotropin, 40 units/mL and 80 units/mL, NDA #008975 - Corticotropin-zinc hydroxide, 40 units/mL, NDA #009854 - Assets will
ANI Pharmaceuticals to Acquire Two NDAs from Merck for $75 Million Transaction Highlights: - Corticotropin, 40 units/mL and 80 units/mL, NDA #008975 - Corticotropin-zinc hydroxide, 40 units/mL, NDA #009854 - Assets will be acquired by foreign subsidiary to achieve more favora
Read more →ANIPANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights For the second quarter 2015: - Net revenues of $19.5 million, an increase of 194% versus second quarter 2014 - Adjusted non-GAAP EBI
ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights For the second quarter 2015: - Net revenues of $19.5 million, an increase of 194% versus second quarter 2014 - Adjusted non-GAAP EBITDA of $10.9 million and operating income of $8.4 million
Read more →ANIPANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results
ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results BAUDETTE, Minn., July 28, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date
Read more →ANIPANI Pharmaceuticals Acquires 22 Generic Drug Products from Teva Pharmaceuticals for $25 million
ANI Pharmaceuticals Acquires 22 Generic Drug Products from Teva Pharmaceuticals for $25 million BAUDETTE, Minn., July 13, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ( ANI ) (NASDAQ: ANIP) today announced that it has acquired 22 previously marketed generic drug products from
Read more →ANIPANI Pharmaceuticals Presents at the UBS Global Healthcare Conference
ANI Pharmaceuticals Presents at the UBS Global Healthcare Conference BAUDETTE, Minn., May 15, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on May 20, 2015 at the UBS Global Healthcare Conference at the Sheraton New York Times Square Hotel in New Yor
Read more →ANIPANI Pharmaceuticals Reports First Quarter 2015 Financial Results For the first quarter 2015: Net revenues of $18.8 million, an increase of 72% over first quarter 2014 Adjusted non-GAAP EBITDA of $11.5 million and operati
ANI Pharmaceuticals Reports First Quarter 2015 Financial Results For the first quarter 2015: Net revenues of $18.8 million, an increase of 72% over first quarter 2014 Adjusted non-GAAP EBITDA of $11.5 million and operating income of $9.6 million, increases of 170% and 174%, re
Read more →ANIPANI Pharmaceuticals Schedules Conference Call for First Quarter 2015 Financial Results
ANI Pharmaceuticals Schedules Conference Call for First Quarter 2015 Financial Results BAUDETTE, Minn., April 28, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2015 financial results on Tuesday,
Read more →ANIPANI Pharmaceuticals Presents At 14th Annual Needham Healthcare Conference
ANI Pharmaceuticals Presents At 14th Annual Needham Healthcare Conference BAUDETTE, Minn., April 7, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on April 14, 2015 at Needham & Company's 14th Annual Healthcare Conference at the Westin Grand Central H
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation February 2015 2 Forward - Looking Statements To the extent any statements made in this presentation de
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation February 2015 2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forwa
Read more →ANIPANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2014 Financial Results For the fourth quarter 2014: Record net revenues of $21.0 million, an increase of 100% over fourth quarter 2013 Record adjusted non-G
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2014 Financial Results For the fourth quarter 2014: Record net revenues of $21.0 million, an increase of 100% over Record adjusted non-GAAP EBITDA of $12.8 million, an increase of 225% over fourth Adjusted non-GA
Read more →ANIPANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2014 Financial Results
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2014 Financial Results BAUDETTE, Minn., Feb. 12, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2014 f
Read more →ANIPANI Pharmaceuticals Announces Appointment of Dr. David Sullivan to VP of Quality Operations
ANI Pharmaceuticals Announces Appointment of Dr. David Sullivan to VP of Quality Operations BAUDETTE, Minn., Feb. 3, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ( ANI ) (NASDAQ: ANIP) today announced the promotion of David J. Sullivan, Ph.D. to the position of Vice President,
Read more →ANIPANI Pharmaceuticals Presents At Oppenheimer 25th Annual Healthcare Conference
ANI Pharmaceuticals Presents At Oppenheimer 25th Annual Healthcare Conference BAUDETTE, Minn., Dec. 11, 2014 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present today at the Oppenheimer & Co. 25th Annual Healthcare Conference at the Crowne Plaza Hotel in New Yo
Read more →ANIPANI Pharmaceuticals Announces Closing of 3.00% Convertible Senior Notes and Full Exercise of Over-Allotment Option BAUDETTE, Minnesota (
ANI Pharmaceuticals Announces Closing of 3.00% Convertible Senior Notes and Full Exercise of Over-Allotment Option BAUDETTE, Minnesota (December 10, 2014) - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (the "Company") today announced that it has closed an underwritten public offe
Read more →ANIPANI Pharmaceuticals Announces Pricing of Upsized $125 Million Convertible Notes Offering
ANI Pharmaceuticals Announces Pricing of Upsized $125 Million Convertible Notes Offering BAUDETTE, Minn., December 5, 2014 - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (the "Company") today announced the pricing of an underwritten public offering of $125,000,000 aggregate princ
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation November 2014 2 Forward - Looking Statements To the extent any statements made in this presentation de
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation November 2014 2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forwa
Read more →ANIPANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights Record net revenues of $17.4 million, an increase of 122% over third quarter 2013 Record adjusted non-GAAP EBITDA of $10
ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights Record net revenues of $17.4 million, an increase of 122% over third quarter 2013 Record adjusted non-GAAP EBITDA of $10.1 million Record adjusted non-GAAP diluted earnings per
Read more →ANIPANI Pharmaceuticals Schedules Conference Call for Third Quarter 2014 Financial Results BAUDETTE, Minnesota (
ANI Pharmaceuticals Schedules Conference Third Quarter 2014 Financial Results BAUDETTE, Minnesota (October 27, 2014) - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2014 financial results on Monda
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCS Corporate Presentation September 2014 2 Forward - Looking Statements To the extent any statements made in this presentation de
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCS Corporate Presentation September 2014 2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forwa
Read more →ANIPANI Reports Second Quarter 2014 Financial Results and Year-To-Date Highlights Recognized net revenues of $6.6 million and adjusted non-GAAP EBITDA of $0.2 million. Recorded $3.9 million in charges that reduced net revenu
ANI Reports Second Quarter 2014 Financial Results and Year-To-Date Highlights Recognized net revenues of $6.6 million and adjusted non-GAAP EBITDA of $0.2 million. Recorded $3.9 million in charges that reduced net revenues, adjusted non-GAAP EBITDA, and net income dollar-for-do
Read more →ANIPANI Pharmaceuticals Acquires Vancocin Capsules and Additional Vancomycin Assets from Shire
ANI Pharmaceuticals Acquires Vancocin Capsules and Additional Vancomycin Assets from Shire BAUDETTE, Minn., Aug. 1, 2014 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) today announced that it has acquired the US rights for Vancocin 125 mg and 250 mg capsules from Shire
Read more →ANIPANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results
ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results BAUDETTE, Minn., July 28, 2014 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2014 financial re
Read more →ANIPANI Pharmaceuticals Acquires Lithobid Extended Release Tablets from Noven Therapeutics
ANI Pharmaceuticals Acquires Lithobid Extended Release Tablets from Noven Therapeutics BAUDETTE, Minn., July 1, 2014 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) today announced that it has acquired the NDA for Lithobid (lithium carbonate extended release 300 mg tabl
Read more →ANIPA Specialty Pharmaceutical Company NASDAQ: ANIP HIGH POTENCY DRUGS - NARCOTIC DRUGS - RX LIQUIDS AND TABLETS - CONTRACT MANUFACTURING Corporate Presentation June 2014
A Specialty Pharmaceutical Company NASDAQ: ANIP HIGH POTENCY DRUGS - NARCOTIC DRUGS - RX LIQUIDS AND TABLETS - CONTRACT MANUFACTURING Corporate Presentation June 2014 2 Cautionary Statement Concerning Forward - Looking Statements This presentation may contain forward - looking s
Read more →ANIPANI Pharmaceuticals Reports Record Net Revenues of $10.9 million, EPS of $0.33, and Adjusted Non-GAAP EBITDA of $4.2 Million for the First Quarter Ended
ANI Pharmaceuticals Reports Record Net Revenues of $10.9 million, EPS of $0.33, and Adjusted Non-GAAP EBITDA of $4.2 Million for the First Quarter Ended March 31, 2014 Baudette, Minnesota (May 5, 2014) - ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial
Read more →ANIPFDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) | Jazz Pharmaceuticals plc
The FDA has issued an approvable letter for Jazz Pharmaceuticals' LUVOX CR for treating social anxiety disorder and OCD, with no safety or efficacy concerns raised. The company is addressing a CMC issue and aims to resolve it promptly.
Read more →ANIPAstraZeneca gets full FDA approval for Arimidex - PharmaTimes
AstraZeneca's Arimidex has received full FDA approval as an adjuvant therapy for early-stage breast cancer in postmenopausal women, demonstrating a 17% reduction in recurrence risk compared to tamoxifen. The drug's sales surged by 50% in the last quarter.
Read more →Competitive Position
How ANIP ranks across every disease it competes inCompetitive Position is a premium feature
See how ANIP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial